Harbour BioMed-B (02142): The New Drug Clinical Trial Application for LET003 Accepted by the National Medical Products Administration
Zhitong Finance APP News, Harbour BioMed-B (02142) announced that the National Medical Products Administration (NMPA) of China has accepted the Company's Investigational New Drug (IND) application for LET003, a next-generation monoclonal antibody targeting ACVR2A/2B developed using the Company's first Hu-mAtrIx AI platform, for the treatment of overweight or obesity. LET003 is a potential best-in-class next-generation monoclonal antibody targeting activin receptors ACVR2A and ACVR2B, which play a key role in regulating muscle-fat metabolic homeostasis.
Latest

